Status:
UNKNOWN
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
Jinan Central Hospital
Conditions:
Severe Acute Respiratory Infection
Community-acquired Pneumonia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Severe Community-acquired pneumonia (SCAP) is a leading global infectious cause of intensive care unit (ICU) admission (approximately 20%-30%), and the primary reason of mortality and morbidity in imm...
Detailed Description
Severe Community-acquired pneumonia (SCAP) is an emergence infection disease of lung parenchyma that acquired outside of a hospital setting. SCAP is a leading global infectious cause of intensive care...
Eligibility Criteria
Inclusion
- Meet the diagnostic criteria of sever community acquired pneumonia (SCAP).
- SCAP is defined as:
- With either one major criterion or at least three minor criteria of the IDSA/ATS CAP severity criteria.
- Admission in ICU.
- Time from SCAP diagnosis to ICU admission\<24 h.
- Patients with Immunocompromised conditions.
- Immunocompromised conditions are defined as:
- Use of long-term (\>3 months) or high-dose (\>0.5 mg/kg/d) steroids.
- Use of other immunosuppressant drugs.
- Solid organ transplantation.
- Solid tumor requiring chemotherapy in the last 5 years.
- Hematologic malignancy regardless of time since diagnosis and received treatments.
- Primary immune deficiency.
- HIV infection with a cluster of differentiation 4 (CD 4) T-lymphocyte count \<200 cells/ml or percentage \<14%.
- Laboratory tests show absolute neutrophil count \< 1,000 cells/µl on ICU admission.
- Other immunosuppression status judged by the physicians.
Exclusion
- Age\<18 years old.
- Pregnant or lactating women.
- Those who are expected to die within 72 h.
- Receiving palliative therapy or supportive treatment only.
Key Trial Info
Start Date :
August 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
342 Patients enrolled
Trial Details
Trial ID
NCT05290454
Start Date
August 19 2022
End Date
September 1 2024
Last Update
January 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong university
Jinan, Shandong, China, 250000